Pathology: breast cancer - adjuvant; es-BC - HER2 negative - (neo)adjuvant (NA); es-BC - TNBC - NA - all population; es-BC - TNBC - NA - PDL1 positive; mBC - TNBC - L1 - all population; mBC - TNBC - L1 - PDL1 positive; mBC - TNBC - L2 - all population; mBC - TNBC - L2 - PDL1 positive;
| breast cancer - adjuvant | es-BC - HER2 negative - (neo)adjuvant (NA) | es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | |||||||||||
| KEYNOTE-522, 2020 | I-SPY2, 2020 | NeoTRIPaPDLA, 0 | IMpassion-031 (all population), 2020 | GeparNuevo, 2019 | KEYNOTE-522, 2020 | IMpassion-031 (PDL1>1%), 2020 | IMpassion-130 (all population), 2018 | IMpassion-131 (all population), 2020 | KEYNOTE-355 (all population), 2020 | IMpassion-130 (PDL1>1%), 2018 | IMpassion-131 (PD-L1 > 1%), 2020 | KEYNOTE-355 (CPS>1), 2020 | KEYNOTE-355 (CPS>10), 2020 | KEYNOTE-119 (all population), 2019 | KEYNOTE-119 (PDL1 CPS>1), 2019 | KEYNOTE-119 (PDL1 CPS>10), 2019 | ||
| pembrolizumab alone | 5 | T1 | T1 | T1 | T1 | T1 | ||||||||||||
| pembrolizumab plus SoC | 3 | T1 | T1 | T1 | ||||||||||||||
| atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | 2 | T1 | T1 | |||||||||||||||
| atezolizumab plus paclitaxel | 2 | T1 | T1 | |||||||||||||||
| atezolizumab plus nab-paclitaxel | 2 | T1 | T1 | |||||||||||||||
| atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | ||||||||||||||||
| pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide | 1 | T1 | ||||||||||||||||
| durvalumab alone | 1 | T1 | ||||||||||||||||
| carboplatin plus nab-paclitaxel | 0 | T0 | ||||||||||||||||
| paclitaxel followed by doxorubicin plus cyclophosphamide | 0 | T0 | ||||||||||||||||
| placebo plus SoC | 0 | T0 | T0 | T0 | T0 | T0 | ||||||||||||
| placebo | 0 | T0 | T0 | T0 | ||||||||||||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||||||||